ZYN 001

Drug Profile

ZYN 001

Alternative Names: D-glyceric acid ester delta 9-tetrahydrocannabinol; Tetrahydrocannabinol prodrug; Tetrahydrocannabinol prodrug transdermal patch; THC prodrug; THC prodrug transdermal patch; ZYN001

Latest Information Update: 07 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Antiemetics; Cannabinoids; Esters; Neuroprotectants; Non-opioid analgesics; Sugar acids
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibromyalgia; Neuropathic pain
  • Preclinical Cancer pain

Most Recent Events

  • 14 Nov 2017 Zynerba Pharmaceuticals plans to initiate a phase II programme in 2018
  • 26 Jun 2017 Phase-I clinical trials in Fibromyalgia (In volunteers) in USA (Transdermal)
  • 26 Jun 2017 Phase-I clinical trials in Neuropathic pain (In volunteers) in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top